Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study

Although Philadelphia chromosome-positive acute leukemia (Ph(+)-ALL) has been revolutionized with tyrosine kinase inhibitors (TKIs), resistance and mutation are universal events during treatment with first-generation and second-generation TKIs. The present third-generation TKI has a dose-dependent,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xu, Wen, Qin, Chen, Guo, Wan, Kai, Liu, Xue, Ma, Ying-Ying, Wang, Mai-Hong, Zhang, Xi, Zhang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997626/
https://www.ncbi.nlm.nih.gov/pubmed/36730312
http://dx.doi.org/10.1097/CAD.0000000000001455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997626/
https://www.ncbi.nlm.nih.gov/pubmed/36730312
http://dx.doi.org/10.1097/CAD.0000000000001455

Ejemplares similares